TrialAmerican journal of hematology2016

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.

Jorge E Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.